Among patients undergoing LT, use of iEPO was associated with similar risks for PGD-3 development and other postoperative outcomes compared with the use of iNO.

A total of 201 randomized patients met eligibility criteria at the time of LT (129 men [64.2%]).

In the intention-to-treat population, 103 patients received iEPO and 98 received iNO.

The primary outcome occurred in 46 of 103 patients (44.7%) in the iEPO group and 39 of 98 (39.8%) in the iNO group, leading to a risk difference of 4.9% (TOST 90% CI, –6.4% to 16.2%; P = .02 for equivalence).

There were no significant between-group differences for secondary outcomes.

Read More